| AE, n (%) . | Onartuzumab (n = 99) . | Placebo (n = 93) . |
|---|---|---|
| Neutropenia | 28 (28.3) | 24 (25.8) |
| Fatigue | 23 (23.2) | 8 (8.6) |
| Pulmonary embolism | 12 (12.1) | 8 (8.6) |
| Peripheral edema | 11 (11.1) | 0 (0.0) |
| Hypertension | 9 (9.1) | 14 (15.1) |
| Neutrophil count decreased | 8 (8.1) | 6 (6.5) |
| Hypokalemia | 7 (7.1) | 9 (9.7) |
| Hyponatremia | 6 (6.1) | 0 (0.0) |
| Deep vein thrombosis | 5 (5.1) | 0 (0.0) |
| White blood cell count decreased | 5 (5.1) | 0 (0.0) |
| Dehydration | 4 (4.0) | 5 (5.4) |
| Nausea | 4 (4.0) | 5 (5.4) |
| Diarrhea | 3 (3.0) | 9 (9.7) |
| Abdominal pain | 3 (3.0) | 6 (6.5) |
| Hyperglycemia | 2 (2.0) | 6 (6.5) |
| AE, n (%) . | Onartuzumab (n = 99) . | Placebo (n = 93) . |
|---|---|---|
| Neutropenia | 28 (28.3) | 24 (25.8) |
| Fatigue | 23 (23.2) | 8 (8.6) |
| Pulmonary embolism | 12 (12.1) | 8 (8.6) |
| Peripheral edema | 11 (11.1) | 0 (0.0) |
| Hypertension | 9 (9.1) | 14 (15.1) |
| Neutrophil count decreased | 8 (8.1) | 6 (6.5) |
| Hypokalemia | 7 (7.1) | 9 (9.7) |
| Hyponatremia | 6 (6.1) | 0 (0.0) |
| Deep vein thrombosis | 5 (5.1) | 0 (0.0) |
| White blood cell count decreased | 5 (5.1) | 0 (0.0) |
| Dehydration | 4 (4.0) | 5 (5.4) |
| Nausea | 4 (4.0) | 5 (5.4) |
| Diarrhea | 3 (3.0) | 9 (9.7) |
| Abdominal pain | 3 (3.0) | 6 (6.5) |
| Hyperglycemia | 2 (2.0) | 6 (6.5) |
Abbreviations: AE, adverse event; Onartuzumab, onartuzumab plus bevacizumab plus mFOLFOX‐6; Placebo, placebo plus bevacizumab plus mFOLFOX‐6.
| AE, n (%) . | Onartuzumab (n = 99) . | Placebo (n = 93) . |
|---|---|---|
| Neutropenia | 28 (28.3) | 24 (25.8) |
| Fatigue | 23 (23.2) | 8 (8.6) |
| Pulmonary embolism | 12 (12.1) | 8 (8.6) |
| Peripheral edema | 11 (11.1) | 0 (0.0) |
| Hypertension | 9 (9.1) | 14 (15.1) |
| Neutrophil count decreased | 8 (8.1) | 6 (6.5) |
| Hypokalemia | 7 (7.1) | 9 (9.7) |
| Hyponatremia | 6 (6.1) | 0 (0.0) |
| Deep vein thrombosis | 5 (5.1) | 0 (0.0) |
| White blood cell count decreased | 5 (5.1) | 0 (0.0) |
| Dehydration | 4 (4.0) | 5 (5.4) |
| Nausea | 4 (4.0) | 5 (5.4) |
| Diarrhea | 3 (3.0) | 9 (9.7) |
| Abdominal pain | 3 (3.0) | 6 (6.5) |
| Hyperglycemia | 2 (2.0) | 6 (6.5) |
| AE, n (%) . | Onartuzumab (n = 99) . | Placebo (n = 93) . |
|---|---|---|
| Neutropenia | 28 (28.3) | 24 (25.8) |
| Fatigue | 23 (23.2) | 8 (8.6) |
| Pulmonary embolism | 12 (12.1) | 8 (8.6) |
| Peripheral edema | 11 (11.1) | 0 (0.0) |
| Hypertension | 9 (9.1) | 14 (15.1) |
| Neutrophil count decreased | 8 (8.1) | 6 (6.5) |
| Hypokalemia | 7 (7.1) | 9 (9.7) |
| Hyponatremia | 6 (6.1) | 0 (0.0) |
| Deep vein thrombosis | 5 (5.1) | 0 (0.0) |
| White blood cell count decreased | 5 (5.1) | 0 (0.0) |
| Dehydration | 4 (4.0) | 5 (5.4) |
| Nausea | 4 (4.0) | 5 (5.4) |
| Diarrhea | 3 (3.0) | 9 (9.7) |
| Abdominal pain | 3 (3.0) | 6 (6.5) |
| Hyperglycemia | 2 (2.0) | 6 (6.5) |
Abbreviations: AE, adverse event; Onartuzumab, onartuzumab plus bevacizumab plus mFOLFOX‐6; Placebo, placebo plus bevacizumab plus mFOLFOX‐6.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
